Rein Therapeutics (RNTX) Live Share Price, Invest From India

Rein Therapeutics Stock Performance

as on November 11, 2026 at 7:24 am IST

Day's Low
Day's High
$0.56
Day's Price Range
$0.62
$0.59
5.15%
Downside
5.01%
Upside
52 Week's Low
52 Week's High
$0.54
52-Week Price Range
$2.10
$0.59
8.52%
Downside
255.69%
Upside

Rein Therapeutics share price movements today

Previous Close: $0.62
Open: $0.61
Volume: 1.3M
Market Cap: $52.9M
Day's Low - High: $0.56 - $0.62
52 Week Low - High: $0.54 - $2.10

Rein Therapeutics Historical Returns

1 Month Return: -21.8 %
3 Month Return: -21.8 %
1 Year Return: -59.68 %
3 Year Return: 0 %
5 Year Return: 0 %

Rein Therapeutics Stock Fundamentals & Key Indicators

Check Rein Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$52.9M

EPS (TTM)

-1.83

Dividend Yield

0.00%

PE Ratio (TTM)

-0.34

Industry PE ratio

-3.08

PEG Ratio

-0.01

Return On Equity TTM

-234.45%

Rein Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Rein Therapeutics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Rein Therapeutics	NA	$52.9M	NA	-0.34	0.00%	0.00%
Moderna	Neutral	$101.5B	17.49%	-35.95	28.00%	0.00%
BeOne Medicines	StrongBuy	$46.5B	NA	66.55	88.39%	0.00%
Vertex Pharmaceuticals	StrongBuy	$138.7B	193.16%	34.94	85.57%	0.00%
Regeneron	Buy	$93.5B	47.86%	19.26	85.77%	0.41%

Stock Returns calculator for Rein Therapeutics Stock including INR - Dollar returns

The Rein Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Rein Therapeutics investment value today

Current value as on today

₹40,590

Returns

-₹59,410

(-59.41%)

Returns from Rein Therapeutics Stock

-₹61,662 (-61.66%)

Dollar Impact

₹2,252 (+2.25%)

Indian Investors' Interest in Rein Therapeutics Stock

Search interest for Rein Therapeutics Stock has decreased by -71% in the last 30 days, reflecting a downward trend in search activity.

Time period: October 12, 2026 to November 11, 2026

Change:-71% versus previous 30 day period

Rein Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-
Operating Income	0	0	0	0	-6	-5	-6	-5	-5	-6
EBITDA	0	0	0	0	-5	-5	-6	-5	-5	-6
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	-	-	0	-	0	-
Income Before Tax	0	0	0	0	-5	-5	-6	-5	-5	-6
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	0	0	0	0	-5	-5	-6	-5	-5	-6
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Rein Therapeutics Annual Profit & Loss

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Revenue	-	-	-	-	-	-	-	-
Gross Profit	0	0	-	-	-	-	-	0
Operating Income	-31	-29	0	0	0	0	-65	-21
EBITDA	-31	-29	0	0	0	0	-28	-50
Interest Expense	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0
Income Before Tax	-31	-29	0	0	0	0	-64	-50
Income Tax Expense	0	0	-	-	-	-	-1	0
Net Income	-31	-28	0	0	0	0	-62	-49
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Rein Therapeutics Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Net Income	-1	-1	-7	-8	-5	-5	-6	-5	-5	-6
Operating Cash Flow	-3	-1	-5	-8	-3	-6	-6	-3	-3	-8
Investing Cash Flow	8	0	-	-	-	-	-	-	-	-35
Financing Cash Flow	-	-	-	18	0	0	4	1	4	47
Change in Cash	5	-1	-5	9	-4	-5	-1	-1	1	4

Rein Therapeutics Annual Cash Flow

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Net Income	-31	-29	-21	-26	-27	-15	-62	-49
Operating Cash Flow	-27	-26	-20	-23	-24	-19	-22	-19
Investing Cash Flow	24	-2	6	-35	26	16	-	-
Financing Cash Flow	2	23	15	55	-	15	17	9
Change in Cash	0	-5	1	-4	1	12	-4	-9

Global Institutional Holdings in Rein Therapeutics

Check out the Institutions with significant holdings in Rein Therapeutics.

Funds	Holdings
VANGUARD INDEX FUNDS	3.84%
Vanguard	3.84%
Voss Capital LLC	1.65%
Fidelity Concord Street Trust	0.67%
BlackRock, Inc.	0.38%

See all

Insights on Rein Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 3 years, Moderna, Inc. Common Stock has given 284.0% return, outperforming this stock by 349.1%
NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 986.4% return, outperforming this stock by 1046.1%
NEGATIVE IMPACT
Price Dip
In the last 7 days, RNTX stock has moved down by -7.0%

About Rein Therapeutics

Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.

Organisation	Rein Therapeutics
Headquarters	12407 N. Mopac Expy., Austin, TX, 78758, US
Industry	Biotechnology
CEO	James Brian Windsor

Key Management of Rein Therapeutics

Name	Title
Ms. Jennifer Faigle	Counsel
Mr. Ron Chen	VP of Finance and Corporate Controller
Dr. James Brian Windsor Ph.D.	CEO, President & Director
Mr. Timothy M. Cunningham CPA, M.B.A.	Interim CFO & Principal Accounting Officer
Dr. Cory M. Hogaboam Ph.D.	Chief Scientific Officer

FAQs

What is Rein Therapeutics share price today?

Rein Therapeutics share price today is $0.59 as on November 11, 2026 at 1:54 am IST. Rein Therapeutics share today touched a day high of $0.62 and a low of $0.56.

What is the 52 week high and 52 week low for Rein Therapeutics share?

Rein Therapeutics share touched a 52 week high of $2.10 on April 22, 2026 and a 52 week low of $0.54 on October 14, 2026. Rein Therapeutics stock price today i.e. November 11, 2026 at 1:54 am IST is trending at $0.59,which is 71.89% down from its 52 week high and 9.31% up from its 52 week low.

What is Rein Therapeutics's market capitalisation today?

Rein Therapeutics market capitalisation is $0.00T as on November 11, 2026 at 1:54 am IST.

How to invest in Rein Therapeutics Stock (RNTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Rein Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Rein Therapeutics Stock (RNTX) from India?

Indian investors can start investing in Rein Therapeutics (RNTX) shares with as little as ₹93.917999267578 or $1 (as of November 11, 2026 at 1:54 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹939.18 in Rein Therapeutics stock (as per the Rupee-Dollar exchange rate as on November 11, 2026 at 1:54 am IST). Based on Rein Therapeutics share’s latest price of $0.59 as on November 11, 2026 at 1:54 am IST, you will get 16.9377 shares of Rein Therapeutics. Learn more about fractional shares .